Advertisement
Screener

enGene Therapeutics Inc. (ENGN) Material Contracts

enGene Therapeutics Inc. Material Contracts

Every material contract the company filed as Exhibit 10 (executive pay plans, credit agreements, supplier and indemnity agreements), newest first, with the filing's own description.

  • 2026-09-08: Form 10-Q; Exhibit 10.11; Description Form of Performance RSU Agreement under the Amended and Restated 2023 Incentive Equity Plan..
  • 2026-09-08: Form 10-Q; Exhibit 10.10; Description Form of Performance Stock Option Agreement under the Amended and Restated 2023 Incentive Equity Plan..
  • 2026-09-08: Form 10-Q; Exhibit 10.9.A; Description Form of Employee Cash Retention Agreement (U.S. version)..
  • 2026-09-08: Form 10-Q; Exhibit 10.9.B; Description Form of Employee Cash Retention Agreement (Canadian version)..
FiledFormExhibitDescription
2026-09-0810-Q10.11Form of Performance RSU Agreement under the Amended and Restated 2023 Incentive Equity Plan.
2026-09-0810-Q10.10Form of Performance Stock Option Agreement under the Amended and Restated 2023 Incentive Equity Plan.
2026-09-0810-Q10.9.AForm of Employee Cash Retention Agreement (U.S. version).
2026-09-0810-Q10.9.BForm of Employee Cash Retention Agreement (Canadian version).
2026-09-0810-Q10.8Form of Executive Cash Retention Agreement.
2026-09-0810-Q10.6Transition Services Agreement and General Release, dated July 8, 2026, by and between enGene, Inc. and Anthony T. Cheung.
2026-09-0810-Q10.5Separation Agreement and General Release, dated July 16, 2026, by and between enGene USA, Inc. and Alexander Nichols.
2026-09-0810-Q10.4Separation Agreement and General Release, dated June 15, 2026, by and between enGene USA, Inc. and Lee G. Giguere.
2026-09-0810-Q10.3Separation Agreement and General Release, dated June 15, 2026, by and between enGene USA, Inc. and Ryan Daws.
2026-09-0810-Q10.2Employment Agreement, dated June 15, 2026, by and between enGene USA, Inc. and William Grossman.
2026-09-0810-Q10.1Employment Agreement, dated June 24, 2026, by and between enGene USA, Inc. and Kathleen Richton.
2026-06-1510-Q10.3Amended and Restated Employment Agreement, dated May 5, 2026, by and between enGene USA, Inc. and Hussein Sweiti.
2026-06-1510-Q10.2Second Amended and Restated Employment Agreement, dated February 27, 2026, by and between enGene Inc. and Anthony T. Cheung.
2026-01-218-K10.1Second Amendment, dated January 20, 2026, to Amended and Restated Loan and Security Agreement dated December 22, 2023, by and among enGene Holdings Inc., enGene Inc. and enGene USA, Inc., as borrower, Hercules Capital, Inc., as agent and lender, and the lenders from time to time party thereto, as amended.*†+
2025-12-2210-K10.32Amended and Restated Employment Agreement, dated October 21, 2024, by and between enGene Inc. and Anthony T. Cheung (incorporated herein by reference to Exhibit 10.32 of enGene’s Annual Report on Form 10-K filed with the SEC on December 19, 2024).#
2025-12-2210-K10.20.BAmendment to Employment Agreement, dated October 2, 2025, by and between enGene USA, Inc. and Ronald H.W. Cooper.#
2025-09-1110-Q10.7Employment Agreement, dated July 8, 2025, by and between enGene USA, Inc. and Matthew Boyd
2025-09-1110-Q10.6Employment Agreement, dated July 8, 2025, by and between enGene USA, Inc. and Jill Buck
2025-06-1210-Q10.3Amended Employment Agreement, dated June 10, 2025, by and between enGene USA, Inc. and Ryan Daws.#
2025-06-1210-Q10.2Employment Agreement, dated May 21, 2025, by and between enGene USA, Inc. and Amy Pott.#
2025-06-108-K10.1enGene Holdings Inc. 2025 Employee Stock Purchase Plan
2025-06-098-K10.2Lease Agreement Guaranty, dated June 4, 2025, by enGene Holdings Inc. in favor of 99 High Street Owner LLC
2025-06-098-K10.199 High Street Office Lease, dated June 4, 2025, by and between 99 High Street Owner LLC and enGene USA, Inc.
2024-12-1910-K10.36First Amendment to Amended and Restated Loan and Security Agreement, dated December 18, 2024. †+
2024-12-1910-K10.34Separation and General Release Agreement, dated October 16, 2024, by and between enGene USA, Inc. and James Sullivan.#
2024-12-1910-K10.33Employment Agreement, dated October 21, 2024, by and between enGene USA, Inc. and Joan Connolly.#
2024-12-1910-K10.32Amended and Restated Employment Agreement, dated October 21, 2024, by and between enGene Inc. and Anthony T. Cheung.#
2024-10-258-K10.1Form of Subscription Agreement, dated October 24, 2024
2024-10-218-K10.1Amended and Restated Employment Agreement, dated October 16, 2024, by and between enGene USA, Inc. and Alexander Nichols.
2024-09-1010-Q10.5Inducement Grant Agreement, dated July 22, 2024, by and between enGene Holdings Inc. and Ronald H. W. Cooper.
2024-09-1010-Q10.4Transition Services Agreement and General Release, dated July 16, 2024, by and between enGene USA, Inc. and Richard Bryce.
2024-09-1010-Q10.3Employment Agreement, dated July 22, 2024, by and between enGene USA, Inc. and Raj Pruthi.
2024-07-248-K10.2Amendment to Transition and Modification Agreement, dated July 23, 2024, by and between enGene USA, Inc. and Jason D. Hanson.*
2024-07-248-K10.1Employment Agreement, dated July 22, 2024, by and between enGene USA, Inc. and Ronald H. W. Cooper.*
2024-06-1410-Q10.2Employment Agreement, dated April 22, 2024, by and between enGene USA, Inc. and Lee Giguere.
2024-05-158-K10.1Amended and Restated enGene Holdings Inc. 2023 Incentive Equity Plan
2024-02-148-K10.2Transition and Modification Agreement, dated February 13, 2024 by and between enGene USA, Inc. and Jason D. Hanson
2024-02-148-K10.1Form of Subscription Agreement, dated February 13, 2024
2023-12-288-K10.1Amended and Restated Loan and Security Agreement, dated December 22, 2023, by and among enGene Holdings Inc., enGene Inc. and enGene USA, Inc., as borrower, Hercules Capital, Inc., as agent, and the lenders from time to time party thereto. *†+
2023-12-138-K10.1Employment Agreement, dated December 13, 2023, by and between enGene USA, Inc. and Ryan Daws.*-
2023-11-298-K10.2Employment Agreement, dated November 29, 2023, by and between enGene USA, Inc. and Richard Bryce.*
2023-11-298-K10.1Employment Offer Letter, dated November 13, 2023, by and between enGene USA, Inc. and Ryan Daws.*
2023-11-098-K10.4Employment Agreement, dated November 8, 2023, by and between enGene Inc. and Anthony Cheung.*-
2023-11-098-K10.3Employment Agreement, dated November 8, 2023, by and between enGene USA, Inc. and James Sullivan.*-
2023-11-098-K10.2Employment Agreement, dated November 8, 2023, by and between enGene USA, Inc. and Alex Nichols.*-
2023-11-098-K10.1Employment Agreement, dated November 8, 2023, by and between enGene USA, Inc. and Jason D. Hanson.*-
2023-10-318-K10.25Form of Indemnification Agreement.*
2023-10-318-K10.24Form of Restricted Stock Unit Award Agreement under enGene Holdings Inc. 2023 Incentive Equity Plan.*
2023-10-318-K10.23Form of Restricted Stock Award Agreement under enGene Holdings Inc. 2023 Incentive Equity Plan.*
2023-10-318-K10.22Form of Incentive Stock Option Grant Agreement under enGene Holdings Inc. 2023 Incentive Equity Plan.*
2023-10-318-K10.21Form of Nonqualified Stock Option Grant Agreement under enGene Holdings Inc. 2023 Incentive Equity Plan.*
2023-10-318-K10.20enGene Holdings Inc. 2023 Incentive Equity Plan.*
2023-10-318-K10.8Registration Rights Agreement, dated October 31, 2023, by and among enGene Holdings Inc., Forbion European Acquisition Corp. and each of the Holders identified therein.*

Similar stocks

Stock NameCountryMarket CapPE Ratio
Neumora Therapeutics, Inc. (NMRA)United States$0.132B-1.48
Armata Pharmaceuticals, Inc. (ARMP)United States$0.132B
Caribou Biosciences, Inc. (CRBU)United States$0.134B-1.79
Tenaya Therapeutics, Inc. (TNYA)United States$0.140B-1.60
LENZ Therapeutics, Inc. (LENZ)United States$0.117B-1.41
Black Diamond Therapeutics, Inc. (BDTX)United States$0.109B-2.48
Humacyte, Inc. (HUMA)United States$0.155B-2.26
Cardiff Oncology, Inc. (CRDF)United States$0.101B-2.22
Outlook Therapeutics, Inc. (OTLK)United States$0.162B-4.90
Acumen Pharmaceuticals, Inc. (ABOS)United States$0.162B-1.83